查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1973758

耳迷走神经刺激设备市场：依产品类型、适应症、最终用户和通路划分－2026-2032年全球预测

Auricular Vagus Nerve Stimulation Devices Market by Product Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，耳迷走神经刺激设备市场价值将达到 4.1601 亿美元，到 2026 年将成长至 4.4374 亿美元，到 2032 年将达到 6.2937 亿美元，复合年增长率为 6.09%。

主要市场统计数据
基准年 2025 4.1601亿美元
预计年份：2026年 4.4374亿美元
预测年份 2032 6.2937亿美元
复合年增长率 (%) 6.09%

耳迷走神经刺激（AVS）的兴起被视为临床实践与技术相结合的机会，并正在重塑神经调节疗法的护理路径。

耳迷走神经刺激（AVS）已从一种小众治疗方法发展成为领先的神经调控疗法，这得益于设备设计的进步、非侵入性刺激通讯协定的建立以及多种适应症临床证据的积累。临床医生和设备研发人员越来越重视AVS疗法，认为它是一种低风险、适合门诊治疗的选择，可以作为侵入性迷走神经刺激和药物疗法的补充。这种转变正吸引着神经病学、疼痛医学、精神病学和基层医疗等多学科团队的关注，并推动着穿戴式电子设备和生物电子医学交叉领域的创新。

技术整合、临床适应症的变化以及不断发展的医疗保健服务模式正在重新定义耳迷走神经刺激疗法的竞争格局和临床前景。

耳迷走神经刺激（AVS）领域正经历着一场变革性的转型，其驱动力包括技术整合、临床应用多元化以及医疗服务模式的变革。小型化电源系统、先进的电极材料以及封闭回路型感测技术的创新降低了居家持续使用的门槛，并实现了更聪明的剂量调整。同时，跨学科临床试验正在拓展其治疗适应症，使其超越传统的神经系统疾病领域，涵盖精神病学、疼痛管理、代谢调节和发炎性疾病，凸显了该疗法在调节全身通路方面的潜力。

2025 年关税变化带来的营运和商业影响促使耳迷走神经刺激 (AURICAL VNS) 领域的相关人员重组其供应链并修改其定价策略。

2025年推出的关税政策引发了连锁反应，影响到耳迷走神经刺激系统设备和子组件的采购决策、定价策略和供应链配置。拥有垂直整合生产结构或多元化供应商基础的製造商更有能力应对不断上涨的成本压力，而依赖单一地区零件采购的小规模创新企业则面临着营运复杂性日益增加的挑战。为此，各组织正在重新审视筹资策略，并加快近岸外包和双重采购的步伐，以维持获利能力并确保供应的连续性。

对器械形状、治疗适应症、医疗环境和通路相互作用，从而影响产品引进途径和商业化选择的机制进行解释。

细分市场分析揭示了产品类型创新、临床适应症的复杂性、终端用户环境的限制以及分销管道的演变等因素驱动的微妙动态。目前的产品类型包括电池供电式刺激器、耳夹式刺激器、耳电极贴片式刺激器、耳机式刺激器和智慧型穿戴式刺激器，每种类型在外形尺寸、电源和使用者接受度方面各有优劣。这些差异会影响处方模式和患者依从性；小型、隐藏的设备适合长期门诊使用，而整合式穿戴装置则支援持续监测和多模态治疗。

美洲、欧洲、中东和非洲以及亚太地区的区域监管、临床和商业性差异导致了采用速度的差异。

耳迷走神经刺激（AVS）的区域趋势反映了美洲、欧洲、中东和非洲以及亚太地区在监管环境、临床实践模式、报销机制和创新生态系统方面的差异。在美洲，创新丛集、部分地区的整合支付系统以及完善的临床研究基础设施支援快速的临床评估和早期商业化部署。然而，要推动AVS在医疗机构的广泛应用，必须展现出显着的卫生经济价值并获得支付者的积极参与。从示范阶段过渡到永续应用阶段，往往取决于可操作的试验数据以及能够清晰阐述AVS比较优势的临床医生的领导角色。

透过整合硬体、软体和临床协作，在竞争差异化方面取得进展，并专注于智慧财产权、设计和证据生成。

耳迷走神经刺激（EVNS）领域的竞争格局呈现出成熟医疗设备製造商、敏捷的专业创新者以及连接电子、软体和临床科学的跨学科合作并存的局面。领先企业正致力于打造硬体、韧体和数位服务的整合产品系列，以增强治疗的个人化和长期依从性。透过投资于整合感测器的封闭回路型系统、取得专利的电极技术以及以用户为中心的设计（旨在减少家庭护理中的摩擦），企业正日益实现策略差异化。

製造商、临床医生和投资者应实施的战术性和策略性倡议，以促进产品应用并确保可持续的市场地位。

产业领导者应优先考虑一系列切实可行的倡议，将临床潜力转化为永续的商业性成果。首先，产品开发应与明确的临床路径和使用者需求保持一致，透过设备人体工学设计、延长电池续航时间和简化介面，减轻临床医生和患者的负担。其次，整合数位健康功能，实现远端监测、药物依从性追踪和疗效评估，加强与支付方的沟通，并支持基于价值的合约。第三，投资于严谨的、针对特异性适应症的证据策略，结合随机试验和真实世界数据收集，以应对疼痛、精神疾病和发炎性疾病等不同适应症中存在的异质性临床终点。

采用透明的多方法研究途径，结合一手访谈、临床文献整合、专利映射和监管审查，以检验策略见解。

本分析的调查方法结合了系统性文献整合、相关人员访谈、医疗设备和专利现状分析，以及对监管和报销框架的定性评估。主要研究包括对神经内科、疼痛管理科、精神科和睡眠医学科的临床医生，以及医院和门诊的采购负责人、医疗设备工程师和业务拓展经理的访谈。次要研究整合了同行评审的临床文献、监管指导文件和公开的技术文檔，以三角验证有关医疗设备性能特征和应用案例的证据。

本报告将临床预期与商业性现实相结合，并概述了成功实施和长期永续性。

耳迷走神经刺激疗法正处于一个转折点，技术成熟、临床需求成长以及医疗服务模式的演变在此交汇，为更广泛的应用铺平了道路。成功与否取决于设备开发商能否将产品创新与严格的特异性证据以及支付方可接受的价值提案相结合。在成本和采购压力持续存在的政策环境下，营运韧性，包括适应性供应链策略和可扩展的生产能力，同样至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：耳迷走神经刺激设备市场：依产品类型划分

  • 电池驱动刺激器
  • 耳夹式刺激器
  • 耳电极贴片刺激器
  • 耳机式刺激器
  • 智慧穿戴刺激器

第九章：耳迷走神经刺激设备市场：依适应症划分

  • 慢性疼痛
    • 肌肉骨骼疼痛
    • 神经病变疼痛
    • 术后疼痛
  • 忧郁症
  • 癫痫
  • 发炎
    • 发炎性肠道疾病
    • 类风湿性关节炎
  • 偏头痛
    • 慢性偏头痛
    • 阵发性偏头痛
  • 肥胖
    • 原发性肥胖
    • 次发性
  • 睡眠障碍
    • 失眠
    • 睡眠呼吸中止症

第十章：耳迷走神经刺激设备市场：依最终用户划分

  • 诊所
  • 居家照护环境
  • 医院
  • 研究机构

第十一章：耳迷走神经刺激设备市场：依通路划分

  • 直销
  • 销售代理
  • 线上零售

第十二章：耳迷走神经刺激设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：耳迷走神经刺激设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 耳迷走神经刺激设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国耳迷走神经刺激设备市场

第十六章：中国耳迷迷走神经刺激设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bioness Inc.
  • Cerbomed GmbH
  • electroCore, Inc.
  • LivaNova PLC
  • Medtronic plc
  • Nervana, LLC
  • NeuroSigma, Inc.
  • Parasym Ltd.
  • ReShape Lifesciences, Inc.
  • Soterix Medical, Inc.
  • Spark Biomedical, Inc.
  • tVNS Technologies GmbH
Product Code: MRR-546E6FBB35F7

The Auricular Vagus Nerve Stimulation Devices Market was valued at USD 416.01 million in 2025 and is projected to grow to USD 443.74 million in 2026, with a CAGR of 6.09%, reaching USD 629.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 416.01 million
Estimated Year [2026] USD 443.74 million
Forecast Year [2032] USD 629.37 million
CAGR (%) 6.09%

Framing the rise of auricular vagus nerve stimulation as a convergent clinical and technological opportunity reshaping neuromodulation care pathways

Auricular vagus nerve stimulation has evolved from a niche modality to a core consideration in the broader neuromodulation toolkit, driven by advances in device ergonomics, noninvasive stimulation protocols, and growing clinical evidence across multiple indications. Clinicians and device developers increasingly view the auricular approach as a lower-risk, outpatient-friendly alternative that complements invasive vagus nerve stimulation and pharmacologic therapies. This shift has elevated attention from multidisciplinary teams spanning neurology, pain medicine, psychiatry, and primary care, and has fostered innovation at the intersection of wearable electronics and bioelectronic medicine.

As interest in personalized and home-based therapies accelerates, device form factors have diversified to address patient comfort, adherence, and discreet use. Regulatory bodies are refining frameworks to accommodate rapid iterations of digital health-enabled stimulators while emphasizing safety, reproducibility, and post-market surveillance. Meanwhile, payer conversations are focusing on evidence demonstrating functional improvement, decreased medication reliance, and health-system efficiencies. These converging trends create an environment where strategic decisions around demonstration studies, interoperability, and user experience can materially influence clinical uptake and long-term viability.

How technological integration, shifting clinical indications, and evolving care delivery models are redefining the auricular VNS competitive and clinical landscape

The landscape for auricular vagus nerve stimulation is undergoing transformative shifts propelled by technological integration, clinical diversification, and changes in care delivery models. Innovations in miniaturized power systems, advanced electrode materials, and closed-loop sensing have reduced barriers to sustained home use and enabled smarter therapy titration. At the same time, cross-disciplinary clinical trials are expanding therapeutic indications beyond classical neurological targets into psychiatry, pain management, metabolic regulation, and inflammatory conditions, highlighting the modality's potential to modulate systemic pathways.

Parallel shifts in health systems, including growth in ambulatory care, telehealth, and remote monitoring, have created new channels for device deployment and patient engagement. Commercial players are rethinking traditional distribution models and partnering with digital therapeutics providers to bundle stimulation with behavioral and monitoring services. Regulatory expectations are evolving to balance patient access with rigorous evidence, prompting manufacturers to adopt adaptive study designs and real-world evidence collection to accelerate labeling and reimbursement conversations. Collectively, these changes demand coordinated strategies that address clinical validation, user experience, regulatory readiness, and supply-chain resilience.

Operational and commercial implications of 2025 tariff shifts that are prompting supply-chain reconfiguration and pricing strategy recalibration for auricular VNS stakeholders

Tariff policies introduced in 2025 have created ripple effects that influence sourcing decisions, pricing strategies, and supply-chain configurations for devices and subcomponents used in auricular vagus nerve stimulation systems. Manufacturers with vertically integrated production or diversified supplier bases have been better positioned to mitigate incremental cost pressures, while smaller innovators dependent on single-region component sourcing have faced heightened operational complexity. In response, organizations have re-evaluated procurement strategies and accelerated nearshoring and dual-sourcing initiatives to preserve margin and ensure continuity of supply.

Parallel to supply-side responses, commercial teams have adjusted pricing architectures and contracting terms to reflect changed landed costs without undermining adoption. Clinical stakeholders and procurement committees have placed greater emphasis on total cost of ownership, including device durability, service models, and consumable usage, when assessing technology selection. Additionally, the tariff environment has catalyzed conversations about design simplification and component standardization to reduce exposure to cross-border policy volatility. These adaptations underscore the importance of agile operations, proven supplier relationships, and proactive scenario planning in sustaining device availability and competitive positioning.

Interpreting how device form factors, therapeutic indications, care settings, and distribution channels interact to shape adoption pathways and commercialization choices

Segmentation analysis reveals nuanced adoption dynamics driven by product type innovation, clinical indication complexity, end-user setting constraints, and distribution channel evolution. Product types now span battery powered stimulators, ear clip stimulators, ear electrode patch stimulators, earphone stimulators, and smart wearable stimulators, each offering distinct trade-offs in form factor, power delivery, and user acceptance. These differences influence prescribing patterns and patient adherence, with smaller, discrete devices favoring chronic outpatient use and integrated wearables supporting continuous monitoring and multimodal therapy delivery.

Indication-based differentiation is similarly consequential. Therapeutic targets under study include chronic pain, depression, epilepsy, inflammation, migraine, obesity, and sleep disorders; chronic pain is further delineated into musculoskeletal pain, neuropathic pain, and postoperative pain, while inflammation encompasses inflammatory bowel disease and rheumatoid arthritis, migraine divides into chronic and episodic presentations, obesity differentiates primary and secondary forms, and sleep disorders separate into insomnia and sleep apnea. These clinical strata demand tailored stimulation parameters, clinical workflows, and evidence packages to demonstrate meaningful patient-level outcomes. End-user environments such as clinics and ambulatory surgical centers, home care settings, hospitals, and research institutes each impose operational requirements and adoption criteria that influence device design, training needs, and support services. Distribution channels ranging from direct sales to distributors and online retail dictate go-to-market cadence, margins, and after-sales support models, with hybrid channel strategies increasingly used to balance reach and service quality. Understanding the interplay across product, indication, setting, and distribution layers enables more precise commercialization and clinical trial planning.

Regional regulatory, clinical, and commercial nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape differential adoption trajectories

Regional dynamics for auricular vagus nerve stimulation reflect differing regulatory frameworks, clinical practice patterns, reimbursement landscapes, and innovation ecosystems across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, innovation clusters, consolidated payer systems in some jurisdictions, and established clinical research infrastructure support rapid clinical evaluations and early commercial rollouts, but they also require demonstrable health-economic value and payer engagement to drive broad institutional adoption. Transitioning from demonstration to sustainable utilization often hinges on pragmatic trial evidence and clinician champions who can articulate comparative benefits.

Across Europe, Middle East & Africa, regulatory harmonization efforts and public procurement processes shape market entry strategies, with national variability in reimbursement pathways and hospital purchasing behavior. Stakeholders operating in this region frequently adopt modular market approaches to align with local clinical guidelines and procurement cycles. The Asia-Pacific region exhibits a mix of highly innovative urban centers and diverse healthcare delivery contexts, where rapid adoption may be enabled by strong digital health infrastructure and high smartphone penetration, but also faces heterogeneity in regulatory oversight and payment mechanisms. For all regions, strategic partnerships with local clinical networks, culturally tailored patient engagement, and robust post-market data collection are critical to translating clinical promise into sustainable adoption.

How competitive differentiation is emerging through integrated hardware, software and clinical partnerships with a focus on IP, design and evidence generation

Competitive dynamics in the auricular vagus nerve stimulation space are characterized by the coexistence of established medical device firms, agile specialized innovators, and multidisciplinary collaborations bridging electronics, software, and clinical science. Leading organizations emphasize integrated product portfolios combining hardware, firmware, and digital services to enhance therapeutic personalization and long-term engagement. Strategic differentiation is increasingly achieved through investments in sensor-enabled closed-loop systems, patented electrode technologies, and user-centered design that reduces friction for at-home therapy administration.

Partnerships between device manufacturers and academic or clinical research centers are accelerating evidence generation, while commercial alliances with digital therapeutics platforms and care management providers are expanding the value proposition beyond stimulation alone. Intellectual property portfolios around stimulation waveforms, biointerface materials, and algorithmic control represent key competitive moats. At the same time, new entrants are leveraging lower-cost manufacturing and direct-to-consumer distribution models to capture niche segments, prompting incumbent firms to refine pricing, service-level agreements, and post-market surveillance capabilities. Ultimately, sustainability in this evolving landscape favors organizations that combine clinical credibility, regulatory acumen, manufacturing reliability, and an ecosystem approach to therapy delivery.

Tactical and strategic initiatives that manufacturers, clinicians, and investors should implement to accelerate adoption and secure durable market positioning

Industry leaders should prioritize a set of actionable initiatives to convert clinical potential into durable commercial outcomes. First, align product development with clearly defined clinical pathways and user needs, ensuring that device ergonomics, battery life, and interface simplicity reduce friction for both clinicians and patients. Second, integrate digital health capabilities that enable remote monitoring, adherence tracking, and outcomes capture to strengthen payer conversations and support value-based contracting. Third, invest in rigorous, indication-specific evidence strategies that combine randomized trials with real-world data collection to address heterogenous clinical endpoints across pain, psychiatric, and inflammatory indications.

Operationally, diversify supplier networks and consider regional manufacturing partnerships to mitigate policy-driven cost pressures and safeguard continuity. Commercially, adopt hybrid distribution models that pair direct relationships with large health systems and targeted online channels for consumer-facing products, while ensuring robust training and service support. Finally, cultivate translational partnerships with academic centers and clinical champions to accelerate adoption, and proactively engage with regulators and payers early to design studies that meet evidentiary expectations. Executed in combination, these initiatives will strengthen market access pathways, reduce implementation friction, and support sustainable growth.

A transparent, multi-method research approach integrating primary interviews, clinical literature synthesis, patent mapping, and regulatory review to validate strategic insights

The research methodology underpinning this analysis combines systematic literature synthesis, stakeholder interviews, device and patent landscape review, and qualitative assessment of regulatory and reimbursement frameworks. Primary engagement included interviews with clinicians across neurology, pain, psychiatry, and sleep medicine, procurement specialists within hospitals and ambulatory centers, device engineers, and business development leaders. Secondary research incorporated peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical resources to triangulate evidence for device performance characteristics and clinical use cases.

Synthesis emphasized cross-validation of insights through multiple sources, and thematic coding was applied to interview transcripts to surface recurrent adoption drivers and barriers. Device design attributes, distribution channels, and end-user requirements were mapped to clinical workflows to identify friction points and opportunity areas. The methodology favored transparency in assumptions, traceability of evidence, and ongoing validation with subject-matter experts to ensure that conclusions remain robust across clinical and commercial contexts.

Synthesizing clinical promise and commercial realities to outline the key determinants of successful adoption and long-term sustainability

Auricular vagus nerve stimulation is positioned at an inflection point where technological maturity, expanding clinical interest, and evolving care delivery models converge to create practical pathways for broader adoption. Success will depend on the ability of device developers to align product innovation with rigorous, indication-specific evidence and payer-acceptable value propositions. Operational resilience, including adaptive supply-chain strategies and scalable manufacturing, will be equally important in a policy environment that introduces periodic cost and sourcing pressures.

Clinician engagement, thoughtful integration of digital capabilities, and strategic partnerships across research, care delivery, and commercial channels will differentiate leaders from followers. By focusing on patient-centered design, robust outcomes measurement, and clear clinical use-case delineation, stakeholders can translate promising early results into therapies that deliver measurable benefits in routine practice. The coming phase will reward organizations that combine scientific rigor with commercial discipline and an ecosystem mindset that places the patient journey at the center of innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Auricular Vagus Nerve Stimulation Devices Market, by Product Type

  • 8.1. Battery Powered Stimulators
  • 8.2. Ear Clip Stimulators
  • 8.3. Ear Electrode Patch Stimulators
  • 8.4. Earphone Stimulators
  • 8.5. Smart Wearable Stimulators

9. Auricular Vagus Nerve Stimulation Devices Market, by Indication

  • 9.1. Chronic Pain
    • 9.1.1. Musculoskeletal Pain
    • 9.1.2. Neuropathic Pain
    • 9.1.3. Postoperative Pain
  • 9.2. Depression
  • 9.3. Epilepsy
  • 9.4. Inflammation
    • 9.4.1. Inflammatory Bowel Disease
    • 9.4.2. Rheumatoid Arthritis
  • 9.5. Migraine
    • 9.5.1. Chronic Migraine
    • 9.5.2. Episodic Migraine
  • 9.6. Obesity
    • 9.6.1. Primary Obesity
    • 9.6.2. Secondary Obesity
  • 9.7. Sleep Disorders
    • 9.7.1. Insomnia
    • 9.7.2. Sleep Apnea

10. Auricular Vagus Nerve Stimulation Devices Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Auricular Vagus Nerve Stimulation Devices Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online Retail

12. Auricular Vagus Nerve Stimulation Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Auricular Vagus Nerve Stimulation Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Auricular Vagus Nerve Stimulation Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Auricular Vagus Nerve Stimulation Devices Market

16. China Auricular Vagus Nerve Stimulation Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bioness Inc.
  • 17.6. Cerbomed GmbH
  • 17.7. electroCore, Inc.
  • 17.8. LivaNova PLC
  • 17.9. Medtronic plc
  • 17.10. Nervana, LLC
  • 17.11. NeuroSigma, Inc.
  • 17.12. Parasym Ltd.
  • 17.13. ReShape Lifesciences, Inc.
  • 17.14. Soterix Medical, Inc.
  • 17.15. Spark Biomedical, Inc.
  • 17.16. tVNS Technologies GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY BATTERY POWERED STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY BATTERY POWERED STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY BATTERY POWERED STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EAR CLIP STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EAR CLIP STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EAR CLIP STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EAR ELECTRODE PATCH STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EAR ELECTRODE PATCH STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EAR ELECTRODE PATCH STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EARPHONE STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EARPHONE STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EARPHONE STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SMART WEARABLE STIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SMART WEARABLE STIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SMART WEARABLE STIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC MIGRAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC MIGRAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC MIGRAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EPISODIC MIGRAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EPISODIC MIGRAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY EPISODIC MIGRAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRIMARY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRIMARY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRIMARY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SECONDARY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SECONDARY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SECONDARY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INSOMNIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP APNEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP APNEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP APNEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 197. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 198. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GCC AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 227. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 237. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY MIGRAINE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY OBESITY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY SLEEP DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA AURICULAR VAGUS NERVE STIMULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)